Plain-English translation of NCT06189170 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage trial testing a new medication called as a potential treatment for Parkinson's disease. Researchers want to understand how safe the medication is, how your body processes it, and how well people tolerate different doses. The study includes both healthy volunteers and people diagnosed with Parkinson's disease.
Parkinson's disease affects millions of people worldwide, and researchers are constantly looking for new treatment options. This trial is designed to see if this medication could be a safe and effective addition to the treatment toolkit for Parkinson's patients.
You likely qualify if…
You likely don't qualify if…
Participants will receive the medication or placebo at the research clinic in increasing doses to see how your body responds. Some participants will receive a single dose, while others will receive multiple doses over time. You'll have regular check-ins with the research team, including blood tests, heart monitoring, and physical exams to track how you're doing and watch for any side effects.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
United Kingdom
Phase
Safety & dosing
Sponsor
Kariya Pharmaceuticals
Enrollment target
~88 participants
Started
August 2024
Primary completion
December 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 80 Years
Last updated on clinicaltrials.gov in March 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Ian Laquian, MBA
MAC
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.